All lobbying filings

TIBER CREEK HEALTH STRATEGIES, INC.

Lobbying for NOVARTIS · Pharmaceutical manufacturer.

Filing 1st Quarter - Report

1st Quarter (Jan 1 - Mar 31) 2025 · District of Columbia · Senate · $60,000.00 income · posted Apr 17, 2025

Official filing document

Bills named in this filing 2

HR 5547
Maintaining Investments in New Innovation Act
S 476
Maintaining Investments in New Innovation Act

Lobbying activity 2

Medicare/Medicaid

Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169); H.R. 5547/S. 476 - Maintaining Investments in New Innovation Act (118th Congress).

Health Issues

Issues related to PBM reform.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.